STRUCTURE-BASED DESIGN OF PROTACS FOR THE DEGRADATION OF SOLUBLE EPOXIDE HYDROLASE
Julia Schönfeld, Steffen Brunst, Ludmila Ciomirtan, Lena Willmer, Michel André ChromikiD, Adarsh M. KumariD, Timo FrömeliD, Nick Liebisch, Arne Hackspacher, Johanna H. M. EhrleriD, Lukas Wintermeier, Christina HesseiD, Jan FiedleriD, Jan HeeringiD, Hinrich FreitagiD, Patrick ZardoiD, Hans‐Gerd FieguthiD, Astrid Brüggerhoff, Josefine Jakob, Björn HäupliD, Lilia WeizeliD, Astrid Kaiser, Manfred Schubert‐Zsilavecz, Thomas OellerichiD, Ingrid FlemingiD, , Kerstin HiesingeriD
Abstract
Soluble epoxide hydrolase (sEH) represents a promising target for inflammation-related diseases as it hydrolyzes highly anti-inflammatory epoxy-fatty acids (EpFAs) to the less active corresponding diols.1 sEH harbours two distinct catalytic domains, the C-terminal hydrolase domain and the N-terminal phosphatase domain which are connected by a proline-rich linker.2 Although potent inhibitors of enzymatic activity are available for both domains, sEH-PROTACs offer the unique ability to simultaneously degrade both domains, mimicking the sEH knockout phenotype associated with beneficial effects as reducing inflammation, attenuating neuroinflammation, and delaying the progression of Alzheimers disease. Herein, we report the structure-based development of a potent sEH-PROTAC as a useful tool compound for the investigation of sEH. In order to facilitate a rapid testing of the synthesized compounds a cell-based sEH degradation assay was developed based on the HiBiT-technology. A structure-activity-relationship (SAR) investigation was performed, based on the crystal structure of previously published sEH inhibitor FL217 where we identified two possible exit vectors. We designed and synthesized a set of 24 PROTACs with varying linkers in a combinatorial manner. Furthermore, co-crystallization of sEH with two selected PROTACs allowed us to explore the binding mode and rationalize the appropriate linker length. After biological and physicochemical investigation, the most suitable PROTAC 23 was identified and applied to degrade sEH in primary human macrophages, marking the successful translation and applicability to non-artificial systems.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 11
- FWCI
- 2.64
- Field percentile
- top 9%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vivo-Active Soluble Epoxide Hydrolase-targeting PROTACs with Improved Potency and Stability
Keita Nakane, Christophe H.P. Morisseau, … Seiya Kitamura·ACS Medicinal Chemistry LettersPeer-reviewed·Oct 3, 2024
- PROTAC-mediated selective degradation of cytosolic soluble epoxide hydrolase enhances ER-stress reduction
Y. Wang, C. Morisseau, … S. Kitamura·bioRxiv·Jan 20, 2022
- Computational design of two new soluble epoxide hydrolase (sEH) inhibitors
J. Liem, S. Adhikari, … J. B. Siegel·bioRxiv·Sep 17, 2020
- Computationally Guided Design of Two Novel Soluble Epoxide Hydrolase Inhibitors
E. C. Dere, S. S. Chu, … J. B. Siegel·bioRxiv·Sep 13, 2022
- Structure-guided design and optimization of covalent VHL-targeted sulfonyl fluoride PROTACs
Rishi R. Shah, Elena De Vita, … Edward W. Tate·Journal of Medicinal ChemistryPeer-reviewed·Mar 13, 2024
- Click Chemistry Enables Rapid Development of Potent sEH PROTACs Using a Direct-to-Biology Approach
Julia Schönfeld, Nick Liebisch, … Kerstin Hiesinger·Chemical CommunicationsPeer-reviewed·Jan 1, 2025